← Search & browse all drugs
CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs) and calcium channel blockers
olmesartan medoxomil and amlodipine
C09DB02
Forms & Strengths
- Tablets: 20mg/5mg, 20mg/10mg, 40mg/5mg, 40mg/10mg
- Combination of olmesartan medoxomil and amlodipine besylate
Adult Dosing
- Usual starting dose: 20mg/5mg once daily
- Maximum dose: 40mg/10mg once daily
- Dose titration at 1-2 week intervals
- Hypertension: adjust dose based on blood pressure response
Pediatric Dosing
- Safety and efficacy not established in pediatric patients under 18 years
- Use is not recommended in pediatric patients
Indications
- Treatment of hypertension alone or with other antihypertensive agents
- Reduction of risk of cardiovascular morbidity and mortality
Mechanism of Action
- Olmesartan: selective angiotensin II receptor antagonist (ARB)
- Amlodipine: dihydropyridine calcium channel blocker (CCB)
- Both components produce additive blood pressure lowering effects
Contraindications
- Hypersensitivity to olmesartan, amlodipine or any component
- Do not co-administer aliskiren with olmesartan in patients with diabetes
Adverse Reactions
- Edema, headache, dizziness, upper respiratory tract infection
- Diarrhea, nausea, fatigue, increased creatinine kinase
- Hypotension, rash, pruritus, arthralgia
Drug Interactions
- Potassium supplements or potassium-sparing diuretics: increased risk of hyperkalemia
- Lithium: increased lithium levels, monitor serum lithium levels
- NSAIDs: decreased antihypertensive effect, increased risk of renal impairment
- CYP3A4 inhibitors: increased exposure to amlodipine, monitor for hypotension
Curated Content: Needs Vetting Before Put to Clinical Use